This special edition episode is brought to you by AmerisourceBergen’s Insights podcast. In Part 2 of this insulin biosimilars series, host Jennifer Kemper, Director of Content Strategy, continues the conversation with Sean McGowan, Senior Director of Biosimilars, Michelle Jesse, Director of Biosimilar Commercialization, and Brad Tallamy, Senior Director of Government Affairs. At the end of July 2021, the biosimilars market expanded with the FDA approving Viatris Inc.’s (aka Mylan) Semglee (insulin glargine-yfgn) as a biosimilar, as well as approving interchangeability status, specific and only to Lantus. The team discusses what these new drugs could mean for the category, how new insulin biosimilars could deliver on the promise of cost-effective care, and how to prepare for interchangeability.